Design Therapeutics (DSGN) Enterprise Value (2020 - 2026)
Design Therapeutics recorded quarterly Enterprise Value of -$222.8 million in Q1 2026, down 1.35% quarter-over-quarter from -$219.8 million in Q4 2025, and up 2.98% year-over-year from -$216.4 million in Q1 2025.
Design Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$222.8 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 2.98% year-over-year to -$222.8 million; the TTM figure through Mar 2026 stood at -$222.8 million (up 2.98% YoY), while the FY2025 annual figure was -$219.8 million, up 10.44% from the prior year.
- Enterprise Value came in at -$222.8 million for Q1 2026 at Design Therapeutics, down from -$219.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$206.0 million in Q3 2025 to a low of -$371.2 million in Q1 2022.
- A 5-year average of -$277.8 million and a median of -$270.7 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value rose 18.93% in 2025 and grew 2.98% in 2026, its largest moves.
- Design Therapeutics' Enterprise Value stood at -$330.4 million in 2022, then gained by 14.71% to -$281.8 million in 2023, then gained by 12.89% to -$245.5 million in 2024, then rose by 10.44% to -$219.8 million in 2025, then slipped by 1.35% to -$222.8 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$222.8 million, -$219.8 million, and -$206.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | -222.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -222.82 Mn |
| Dec 31, 2025 | -219.85 Mn |
| Sep 30, 2025 | -205.97 Mn |
| Jun 30, 2025 | -216.28 Mn |
| Mar 31, 2025 | -229.67 Mn |
| Dec 31, 2024 | -245.48 Mn |
| Sep 30, 2024 | -254.07 Mn |
| Jun 30, 2024 | -261.02 Mn |
| Mar 31, 2024 | -270.69 Mn |
| Dec 31, 2023 | -281.80 Mn |
| Sep 30, 2023 | -290.94 Mn |
| Jun 30, 2023 | -303.09 Mn |
| Mar 31, 2023 | -315.39 Mn |
| Dec 31, 2022 | -330.39 Mn |
| Sep 30, 2022 | -344.23 Mn |
| Jun 30, 2022 | -359.38 Mn |
| Mar 31, 2022 | -371.22 Mn |
| Dec 31, 2021 | -384.06 Mn |
| Sep 30, 2021 | -357.77 Mn |
| Jun 30, 2021 | -402.84 Mn |
| Mar 31, 2021 | -400.78 Mn |
| Dec 31, 2020 | -2.43 Mn |